Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Timolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.98 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.83 |
| ▸ | BLM | P54132 | 1/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Timolol SCHEMBL8858730 | 1.00 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL8858736 | 1.00 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL222970 | 0.99 | CYP1A2 (1.00) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL2553603 | 0.99 | CYP1A2 (1.00) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL1587691 | 0.99 | CYP1A2 (1.00) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL4912 | 0.99 | CYP1A2 (1.00) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL2356059 | 0.98 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL7591293 | 0.98 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL5539013 | 0.98 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A | |
| Timolol SCHEMBL16094075 | 0.98 | CYP1A2 (0.98) | CYP1A2ADRB2ADRB1CYP3A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 950 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724839-A2 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | Mediprint Ophthalmics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260090984-A1 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | MEDIPRINT OPHTHALMICS INC. (US) | 2026-04-02 | — | — | US | claimed |
| EP-4626373-A2 | BIO-ERODIBLE OCULAR IMPLANTS FOR TREATMENT OF CONDITIONS OF THE EYE | Sight Sciences, Inc. (US) | 2025-10-08 | — | — | EP | claimed |
| EP-4555375-A1 | METHODS OF MAKING AND USING CONTACT LENSES INCLUDING MEDICAMENTS AND STABILIZERS OF LABILE COMPONENTS SUCH AS DRUGS | Doshi, Praful (US) | 2025-05-21 | — | — | EP | claimed |
| US-12178904-B2 | Contact lenses including medicaments and methods of making and using same including stabilizers of labile components such as drugs | MEDIPRINT OPHTHALMICS INC. | 2024-12-31 | — | — | US | claimed |
| WO-2024254134-A2 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | MEDIPRINT OPHTHALMICS INC. (US) | 2024-12-12 | — | — | WO | claimed |
| US-20240285522-A1 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING STABILIZERS OF LABILE COMPONENTS SUCH AS DRUGS | MEDIPRINT OPHTHALMICS INC. | 2024-08-29 | — | — | US | claimed |
| WO-2024118686-A2 | BIO-ERODIBLE OCULAR IMPLANTS FOR TREATMENT OF CONDITIONS OF THE EYE | SIGHT SCIENCES, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| WO-2024015959-A1 | METHODS OF MAKING AND USING CONTACT LENSES INCLUDING MEDICAMENTS AND STABILIZERS OF LABILE COMPONENTS SUCH AS DRUGS | DOSHI PRAFUL (US) | 2024-01-18 | — | — | WO | claimed |
| CN-113057794-B | Ophthalmic drug delivery device and method of making same | 财团法人工业技术研究院 | 2023-03-10 | — | — | CN | claimed |
| US-5541184-A | S-timolol hemihydrate treatment process | LEIRAS OY (FI) | 1996-07-30 | — | — | US | claimed |
| WO-1995026712-A1 | OPHTHALMIC COMPOSITION CONTAINING AN ION SENSITIVE, HYDROPHILIC POLYMER AND AN INORGANIC SALT IN A RATIO WHICH GIVES LOW VISCOSITY | LEIRAS OY (FI) | 1995-10-12 | — | — | WO | claimed |
| EP-0655911-A1 | OPHTHALMOLOGICAL PREPARATION | LEIRAS OY (FI) | 1995-06-07 | — | — | EP | claimed |
| US-5354860-A | Process for making pure S-timolol hemihydrate | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 1994-10-11 | — | — | US | claimed |
| WO-1994004134-A1 | OPHTHALMOLOGICAL PREPARATION | LEIRAS OY (FI) | 1994-03-03 | — | — | WO | claimed |
| WO-1994001115-A1 | OPHTHALMIC TOPICAL COMPOSITION CONTAINING (S)-TIMOLOL HEMIHYDRATE | LEIRAS OY (FI) | 1994-01-20 | — | — | WO | claimed |
| EP-0577913-A1 | Pharmaceutical preparation | LEIRAS OY (FI) | 1994-01-12 | — | — | EP | claimed |
| US-5231095-A | S-TIMOLOL HEMIHYDRATE | LEIRAS OY (FI) | 1993-07-27 | — | — | US | claimed |
| EP-0440684-A1 | NOVEL S-TIMOLOL DERIVATIVE AND PROCESS FOR ITS PREPARATION. | HUHTAMAEKI YHTHYMAE OY (FI) | 1991-08-14 | — | — | EP | claimed |
| WO-1990004592-A1 | NOVEL S-TIMOLOL DERIVATIVE AND PROCESS FOR ITS PREPARATION | Huhtamäki Oy (FI) | 1990-05-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260090984-A1 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | RPL26, PCTP, RPS24 | ADRB2 2644/4885ADRB1 3542/4885CYP1A2 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.